PERRIGO Co plc
PRGO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRGO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRGO
Perrigo Co plc is a global provider of over-the-counter (OTC) health and wellness solutions and infant formula, focused on stabilizing its store brand business and streamlining its portfolio through divestitures and cost-saving programs.
Key risk: Regulatory and litigation risks
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 27, 2026.
Tracking 1 pipeline candidate · 1 clinical trial · 5 FDA decisions for PERRIGO Co plc.
Perrigo Co plc is a global provider of over-the-counter (OTC) health and wellness solutions and infant formula, focused on stabilizing its store brand business and streamlining its portfolio through divestitures and cost-saving programs.
- Perrigo achieved gross annualized pre-tax savings of approximately $163 million from its 'Project Energize' streamlining program [sec · filed 2026-03-20].
- The company announced the divestiture of its Dermacosmetics business for up to €327 million and strategic reviews for its Infant Formula and Oral Care businesses [sec · filed 2026-03-20].
- Perrigo stabilized its store brand business with solid share and distribution gains and recovered infant formula service levels above 90% [sec · filed 2026-03-20].
- As of the latest financials (2026-06-27), Perrigo reported cash & equivalents of $399.7M, total revenue of $1,022.8M, net income of $74.5M, shareholders' equity of $2,935.5M, and total debt of $21.9M [sec].
What works
- Perrigo successfully completed 'Project Energize' with savings at the high end of its estimated range, indicating effective cost management [sec · filed 2026-03-20].
- The company stabilized its store brand business and infant formula supply, with service levels recovering above 90% despite competitive pressures [sec · filed 2026-03-20].
- Perrigo is streamlining its portfolio by divesting non-core assets (Dermacosmetics) and reviewing others, which may sharpen focus on core categories [sec · filed 2026-03-20].
What to weigh
- Perrigo faces ongoing risks from government investigations, regulatory initiatives, and potential product recalls or sales halts [sec · filed 2025-07-14].
- The company's development and commercialization of new products is time-consuming and costly, with no guarantee of regulatory approval or market success [sec_mda · as of 2026-02-26].
- Perrigo's business is exposed to macroeconomic uncertainties including tariffs, geopolitical conflicts, and currency fluctuations [sec · filed 2025-07-14].
From the filings
Quoted directly from source documents.
Project Energize achieved savings at the high end of the estimated range.
“Successfully completed 'Project Energize' streamlining efforts, which achieved gross annualized pre-tax savings gross ofapproximately $163 million, towards the high-end of the Company's estimated range of $140 million to $170 million.”
SEC filings · March 20, 2026
Perrigo stabilized its store brand business and infant formula supply.
“We stabilized our store brandbusiness evidenced by solidshare and distribution gains. Wealso stabilized supply in InfantFormula, recovering servicelevels above 90%, even asdemand recovery slowed andcompetition intensified.”
SEC filings · March 20, 2026
Perrigo announced divestiture of Dermacosmetics and strategic reviews for Infant Formula and Oral Care.
“Further streamlined the portfolio by announcing the agreement to divest our Dermacosmetics business for up to €327 Million;separately announced strategic reviews for the Infant Formula and Oral Care businesses.”
SEC filings · March 20, 2026
Product development is subject to high business risk and regulatory uncertainty.
“The development and commercialization process, particularly with respect to innovative products, is both time consuming and costly, and subject to a high degree of business risk.”
SEC MD&A · February 26, 2026
Risks & what to watch (4)›
Key risks
- Regulatory and litigation risks — Ongoing government investigations, regulatory initiatives, and potential product recalls could impact operations [sec · filed 2025-07-14].
- Product development failure
- Macroeconomic and geopolitical exposure — Tariffs, armed conflicts, and currency fluctuations could adversely affect financial results [sec · filed 2025-07-14].
- Supply chain disruptions — Supply chain impacts from armed conflict, sanctions, or disease remain a risk [sec · filed 2025-07-14].
What to watch
- Progress on the divestiture of Dermacosmetics and outcomes of strategic reviews for Infant Formula and Oral Care [sec · filed 2026-03-20].
- Ability to sustain store brand market share and infant formula service levels above 90% amid competition [sec · filed 2026-03-20].
- Execution of the new growth model focused on Category Leadership and Market Activation [sec · filed 2026-03-20].
- Resolution of ongoing litigation, tax assessments, and regulatory matters [sec_mda · as of 2026-08-05].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PERRIGO Co plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PERRIGO Co plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
10.5 months
D/E 2.02 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
328
Total value held
$1.44B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 17,120,084 | $183.9M |
| vanguard capital management llc | 12,419,074 | $133.4M |
| neuberger berman group llc | 10,460,080 | $112.3M |
| vanguard portfolio management llc | 8,141,919 | $87.4M |
| fuller & thaler asset management, inc. | 7,662,883 | $82.3M |
| state street corp | 7,225,395 | $77.6M |
| dimensional fund advisors lp | 6,567,616 | $70.5M |
| millennium management llc | 4,279,731 | $46.0M |
| menora mivtachim holdings ltd. | 3,872,000 | $41.6M |
| morgan stanley | 2,776,642 | $29.8M |
Showing top 10 of 328 institutional holders of PERRIGO Co plc. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 15.6%
- Days to cover
- 3.8
- Shares short
- 13,922,505
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRGO short interestGovernance
Frequently asked questions
What is the AI investment thesis for PERRIGO Co plc?
Perrigo Co plc is a global provider of over-the-counter (OTC) health and wellness solutions and infant formula, focused on stabilizing its store brand business and streamlining its portfolio through divestitures and cost-saving programs.
What is PERRIGO Co plc's lead drug candidate?
PERRIGO Co plc's most advanced tracked candidate is nasonex 24hr allergy (Approved) for Uses temporarily relieves these symptoms of hay fever or other upper respiratory allergies: • nasal congestion • runny nose • sneezing • itchy nose.
Who is the CEO of PERRIGO Co plc?
Mr. Albert Ange Manzone is the chief executive officer of PERRIGO Co plc (PRGO).
Where is PERRIGO Co plc headquartered?
PERRIGO Co plc (PRGO) is headquartered in Dublin, Ireland.
What therapeutic areas does PERRIGO Co plc focus on?
PERRIGO Co plc develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.